Key result
Catalpol improves viability and reduces doxorubicin-induced oxidative stress in H9C2 cardiomyoblasts by activating PPAR-γ.
Why the study?
Drug-induced cardiomyopathy causes severe refractory heart disease, with doxorubicin-induced cell damage primarily mediated by cellular oxidative stress.
Population
H9C2 cardiomyocytes
Comparison
Catalpol vs doxorubicin alone
Design
In vitro laboratory study
Authors
Loading...
Hypothesis-generating for catalpol in doxorubicin cardiomyopathy; leaves open clinical translation pending in vivo and human studies.
p-value: p=<0.05
Catalpol protects H9C2 cardiomyoblasts against doxorubicin-induced inflammation and oxidative stress by activating PPAR-γ, suggesting a potential therapeutic mechanism for drug-induced cardiomyopathy.
Jiang et al. (2020) studied Doxorubicin-induced cardiomyopathy. Catalpol vs. Doxorubicin (1 µM) alone was evaluated on H9C2 cell viability (p=<0.05). Catalpol significantly increased cell viability and ameliorated doxorubicin-induced inflammation and oxidative stress in H9C2 cardiomyoblasts by activating PPAR-γ.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: